Agilent Technologies（A）株式概要
Agilent Technologies, Inc.は、ライフサイエンス、診断、応用化学の各市場にアプリケーションに特化したソリューションを世界中に提供しています。 詳細
報酬
リスク分析
リスクチェックの結果、A 、リスクは検出されなかった。
A Community Fair Values
Create NarrativeSee what 47 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Pharmaceuticals & Biotech opportunity
Agilent Technologies, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$117.69 |
| 52週高値 | US$160.27 |
| 52週安値 | US$104.79 |
| ベータ | 1.22 |
| 1ヶ月の変化 | 2.48% |
| 3ヶ月変化 | -9.22% |
| 1年変化 | 9.46% |
| 3年間の変化 | -8.10% |
| 5年間の変化 | -8.51% |
| IPOからの変化 | 175.30% |
最新ニュース
ナラティブ更新 • Apr 25
A: New Diagnostic Approvals And Buybacks Will Support Long Term Upside
Analysts have trimmed their price target on Agilent Technologies by about $1 to $160.69, reflecting slightly adjusted views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News The Supreme Court of the United States denied Agilent Technologies' petition related to two CRISPR guide RNA patents, leaving in place prior rulings that found all claims of the patents unpatentable.ナラティブ更新 • Apr 09
A: New Diagnostic Expansion And Guidance Will Support Long Term Upside
Analysts have slightly reduced their price target on Agilent Technologies by about $1, citing updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. They indicate that the overall outlook remains largely intact.Recent updates
ナラティブ更新 • Apr 25
A: New Diagnostic Approvals And Buybacks Will Support Long Term Upside
Analysts have trimmed their price target on Agilent Technologies by about $1 to $160.69, reflecting slightly adjusted views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News The Supreme Court of the United States denied Agilent Technologies' petition related to two CRISPR guide RNA patents, leaving in place prior rulings that found all claims of the patents unpatentable.ナラティブ更新 • Apr 09
A: New Diagnostic Expansion And Guidance Will Support Long Term Upside
Analysts have slightly reduced their price target on Agilent Technologies by about $1, citing updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. They indicate that the overall outlook remains largely intact.ナラティブ更新 • Mar 26
A: New Diagnostic Approval Will Drive Upside For Long Term Outlook
Analysts have made a slight trim to their price target for Agilent Technologies to about $163.19 from around $163.29, citing updated assumptions for revenue growth, profit margins and a somewhat lower future P/E multiple. What's in the News The FDA approved Agilent's PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to help identify first line patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma who may be eligible for treatment with KEYTRUDA, adding a seventh companion diagnostic indication for this assay (Key Developments).ナラティブ更新 • Mar 11
A: New Diagnostic Approvals And Digital Pathology Expansion Will Drive Upside
Analysts have trimmed their price target on Agilent Technologies to about $163 from roughly $170, citing modest tweaks to their models, including slightly adjusted revenue growth, discount rate, profit margin, and future P/E assumptions. What's in the News Agilent issued earnings guidance for fiscal Q2 2026, with revenue expected in the range of $1.79b to $1.82b, framed as approximately 7% to 9% reported growth and 4% to 5.5% core growth (company guidance).Seeking Alpha • Mar 10
Why Agilent Technologies Just Paid $950 Million For Biocare Medical
Summary Agilent Technologies (A) acquires Biocare Medical for $950M to expand into high-growth pathology and cancer diagnostics, enhancing recurring consumables revenue streams. A trades below historical valuation multiples, presenting an opportunity if management executes on diagnostics expansion and leverages its global distribution to scale Biocare’s offerings. 1Q26 results showed 7% reported revenue growth to $1.80B, with non-GAAP EPS up 4% year-over-year, and management raised FY26 guidance for both revenue and EPS. The Biocare deal accelerates Agilent’s shift toward higher-margin, recurring revenue, with management expecting positive EPS contribution within 12 months post-close. Read the full article on Seeking Alphaナラティブ更新 • Feb 25
A: New Diagnostic Approvals Will Support Measured Upside Ahead
Analysts reaffirm a price target of $169.67 for Agilent Technologies, citing largely unchanged assumptions for the discount rate, revenue growth, profit margin, and future P/E. These factors together keep their valuation framework intact.ナラティブ更新 • Feb 10
A: New Digital Pathology And Board Declassification Will Support Measured Upside Ahead
Analysts have modestly trimmed their price target on Agilent Technologies to reflect slightly higher discount rate assumptions and a lower future P/E, while still incorporating steady revenue growth and a marginally stronger profit margin outlook. What's in the News Agilent plans to ask shareholders at the March 18, 2026 AGM to approve an amendment to its Third Amended and Restated Certificate of Incorporation that would declassify the board of directors over three years, shifting toward annual director elections (Key Developments).ナラティブ更新 • Jan 26
A: New Digital Pathology And Buybacks Will Support Measured Upside Ahead
Analysts have nudged their price target on Agilent Technologies slightly higher to about US$170, citing updated assumptions around fair value, discount rates, revenue growth, profit margins and future P/E, which collectively support a modest upward revision. What's in the News Agilent launched the S540 MD Slide Scanner System for whole slide imaging in key European markets, adding a high throughput digital pathology scanner with capacity for 540 slides and AI assisted tissue detection to its portfolio (Product Related Announcements).ナラティブ更新 • Jan 11
A: New CFO And Capital Returns Will Support Measured Upside Ahead
Analysts have nudged their price target for Agilent Technologies slightly lower to US$168.59 from US$169.44, citing small adjustments to their fair value estimate, discount rate, revenue growth outlook, profit margin assumptions, and future P/E expectations. What's in the News Agilent outlined fiscal first quarter 2026 revenue guidance of US$1.79b to US$1.82b and fiscal 2026 revenue guidance of US$7.3b to US$7.4b, with both ranges expressed in reported and core terms (Corporate guidance).分析記事 • Dec 18
Agilent Technologies (NYSE:A) Is Increasing Its Dividend To $0.255
Agilent Technologies, Inc. ( NYSE:A ) has announced that it will be increasing its dividend from last year's comparable...ナラティブ更新 • Dec 15
A: New Leadership And Compliance Software Will Support Measured Upside Ahead
Analysts have nudged their average price target on Agilent Technologies higher by about $2 to roughly $169.44, citing slightly faster expected revenue growth and a modestly lower discount rate that more than offset a small downward revision to long term profit margins. What's in the News Launched 21 CFR Part 11 compliant software for the xCELLigence RTCA eSight system, enabling secure deployment in GMP manufacturing and QC labs with features such as secure logins, e-signatures, and full audit trails (Key Developments).ナラティブ更新 • Nov 30
A: New Diagnostic Solutions And Leadership Will Shape Measured Prospects Ahead
Analysts have raised their price target for Agilent Technologies from $152.33 to $167.57, citing modestly higher expectations for revenue growth and valuation metrics as the primary reasons for the change. What's in the News Agilent Technologies provided earnings guidance for fiscal Q1 2026, expecting revenue in the range of $1.79 billion to $1.82 billion, up 6% to 8% reported and 4% to 6% core.分析記事 • Nov 27
Agilent Technologies, Inc. (NYSE:A) Analysts Are Pretty Bullish On The Stock After Recent Results
It's been a good week for Agilent Technologies, Inc. ( NYSE:A ) shareholders, because the company has just released its...ナラティブ更新 • Nov 16
A: Product Launches And Diagnostic Approval Will Support Balanced Outlook
Narrative Update: Agilent Technologies Analyst Price Target Revision Analysts have raised their price target for Agilent Technologies from $149.90 to $152.33. This change reflects modest upward revisions in projected revenue growth and a slightly higher expected future valuation multiple.ナラティブ更新 • Nov 01
A: Global Healthcare Trends And New Diagnostic Solutions Will Shape Future Performance
Analysts have slightly raised their price target for Agilent Technologies from $148.57 to $149.90, citing stable fundamentals and a modest valuation adjustment. What's in the News Adam S.ナラティブ更新 • Oct 18
Global Healthcare Demand And PFAS Testing Will Drive Analytical Progress
Analysts have raised their price target for Agilent Technologies from $140.97 to $148.57, citing improved revenue growth prospects and higher expected profit margins as key drivers behind the upward revision. What's in the News Announced launch of Insight Series Alarm Resolution Systems, which enhance airport security checkpoints with advanced liquid explosive detection and adaptability to changing regulations (Product Related Announcements).ナラティブ更新 • Oct 04
Global Healthcare Demand And PFAS Testing Will Drive Analytical Progress
Agilent Technologies received a modest analyst price target increase from $138.83 to $140.97. This reflects analysts' expectations for stable growth and slightly improved long-term valuation metrics.ナラティブ更新 • Sep 16
Global Healthcare Demand And PFAS Testing Will Drive Analytical Progress
Agilent Technologies’ fair value estimates have remained stable, as reflected by marginal changes in both the consensus analyst price target (up slightly to $138.83) and the forward P/E (now 27.33x). What's in the News Raised full-year 2025 revenue guidance to $6.91–$6.93 billion, up 6.2–6.5% reported and 4.3–4.6% core, reflecting a $150 million increase at the midpoint and 1.5 points higher core growth.分析記事 • Aug 03
Estimating The Intrinsic Value Of Agilent Technologies, Inc. (NYSE:A)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Agilent Technologies fair value estimate is US$114 With US$114...分析記事 • Jul 01
What Is Agilent Technologies, Inc.'s (NYSE:A) Share Price Doing?
Today we're going to take a look at the well-established Agilent Technologies, Inc. ( NYSE:A ). The company's stock saw...Seeking Alpha • Apr 24
City Office REIT (RED PFD SER A): A High Yield, Deep Value Opportunity Worth Latching Onto
Summary City Office REIT's Series A Preferred Shares offer a tempting yield despite recent accounting losses and systemic pressures, suggesting a potential buying opportunity. The shares are cumulative, redeemable, and fixed, ensuring eventual dividend payments, though call risk and financial restructuring are potential concerns. The REIT's fundamentals, including an 85.8% occupancy rate and sector diversification, support sustainability, with positive economic profitability and AFFO figures. Despite macroeconomic risks, Series A's deep discount and commendable yield, along with manageable leverage ratios, led to us deeming it a 'Buy.' Read the full article on Seeking AlphaSeeking Alpha • Apr 07
Tariffs And Tactics: Agilent's Path Through Trade Disruption
Summary The April 2025 "Liberation Day" tariffs impose a 10% baseline tariff on all imports and additional surcharges, significantly impacting Agilent Technologies' cost structure and supply chain. Agilent's diversified global manufacturing footprint and strategic localization in China help mitigate some tariff impacts, but higher costs and competitive pressures remain concerns. Despite initial projections of modest financial impact, prolonged tariffs could necessitate further operational shifts, including relocating production and localizing R&D to maintain market access. Agilent's strong brand, advanced technology, and flexible supply chain position it to navigate tariff challenges, with potential long-term benefits from a more resilient global network. Read the full article on Seeking AlphaSeeking Alpha • Mar 01
Agilent Technologies: Recent Price Weakness Makes This Stock A Buy
Summary Agilent Technologies, a leader in life sciences and diagnostics, has a market cap of $38B and a 10-year CAGR of 13.6%. Key financial metrics: consistent revenue growth, stable gross profit margin above 50%, and a robust return on invested capital, despite some fluctuations. The stock fell too far after its recent earnings report, making it too good to pass up at its current level. Read the full article on Seeking Alpha株主還元
| A | US Life Sciences | US 市場 | |
|---|---|---|---|
| 7D | 5.7% | 4.3% | 3.2% |
| 1Y | 9.5% | 7.9% | 31.0% |
業界別リターン: A過去 1 年間で7.9 % のリターンをもたらしたUS Life Sciences業界と一致しました。
リターン対市場: Aは、過去 1 年間で31 % のリターンを上げたUS市場を下回りました。
価格変動
| A volatility | |
|---|---|
| A Average Weekly Movement | 4.2% |
| Life Sciences Industry Average Movement | 8.1% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
安定した株価: A 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: Aの 週次ボラティリティ ( 4% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1999 | 18,000 | Padraig McDonnell | www.agilent.com |
アジレント・テクノロジーは、ライフサイエンス、診断、応用化学の各市場にアプリケーションに特化したソリューションを世界中に提供している。同社は3つのセグメントで事業を展開している：Life Sciences and Diagnostics Markets、Agilent CrossLab、Applied Markets。ライフサイエンス・診断市場部門は、液体クロマトグラフィーシステムおよびコンポーネント、液体クロマトグラフィー質量分析システムを提供している。また、ゲノミクス事業、開発・製造受託事業、病理事業、コンパニオン診断薬事業、生体分子解析事業にも取り組んでいます。Agilent CrossLab事業では、修理、部品、メンテナンス、設置、トレーニング、コンプライアンスサポート、Software as a Service、資産管理、コンサルティング、その他カスタムサービスなどの各種サービスを提供しています。また、ガスクロマトグラフィーカラム、液体クロマトグラフィーカラム、サンプル前処理製品、カスタムケミストリ、各種ラボ用品などの消耗品、機器制御、データ収集、データ解析、結果の安全な保存、ラボ情報およびワークフロー管理用ソフトウェアからなるソフトウェアおよびインフォマティクスソリューション、ラボ全体および企業全体で科学データを収集、解析、共有できるオープンソフトウェアプラットフォームであるOpenLabラボソフトウェアも提供している。さらに、リキッドハンドリング、プレート管理、消耗品、スケジューリングソフトウェアなどの自動サンプル前処理ソリューションも提供している。Applied Markets部門は、ガスクロマトグラフィー、質量分析、分光学、真空技術、再販機器の分野で製品を提供している。直販、代理店、再販業者、メーカー代理店、電子商取引を通じて製品を販売している。アジレント・テクノロジーは1999年に設立され、カリフォルニア州サンタクララに本社を置いている。
Agilent Technologies, Inc. 基礎のまとめ
| A 基礎統計学 | |
|---|---|
| 時価総額 | US$33.21b |
| 収益（TTM） | US$1.29b |
| 売上高(TTM) | US$7.07b |
25.8x
PER（株価収益率4.7x
P/SレシオA は割高か？
公正価値と評価分析を参照収益と収入
| A 損益計算書（TTM） | |
|---|---|
| 収益 | US$7.07b |
| 売上原価 | US$3.37b |
| 売上総利益 | US$3.70b |
| その他の費用 | US$2.41b |
| 収益 | US$1.29b |
直近の収益報告
Jan 31, 2026
次回決算日
May 27, 2026
| 一株当たり利益（EPS） | 4.56 |
| グロス・マージン | 52.30% |
| 純利益率 | 18.26% |
| 有利子負債／自己資本比率 | 48.6% |
A の長期的なパフォーマンスは？
過去の実績と比較を見る配当金
0.9%
現在の配当利回り22%
配当性向企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/06 21:23 |
| 終値 | 2026/05/06 00:00 |
| 収益 | 2026/01/31 |
| 年間収益 | 2025/10/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Agilent Technologies, Inc. 17 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。34
| アナリスト | 機関 |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Charles Butler | Barclays |
| Luke Sergott | Barclays |